Clinical trials · Washington, D.C., DC
Platinum-resistant Ovarian Cancer clinical trials in Washington, D.C.
We’re tracking 18 recruiting platinum-resistant ovarian cancer studies with a site in or near Washington, D.C. — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Washington, D.C.
- NCT07023627RecruitingPhase 2
New pill for platinum-resistant ovarian cancer with cyclin E1
This study tests a new pill called INCB123667 for people with a type of ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if the drug can shrink tumors or slow their growth.
Washington D.C., District of ColumbiaAges 18–99 - NCT07218809RecruitingPhase 3
Comparison of AZD5335 vs standard treatments for advanced ovarian cancer
This trial tests a new drug, AZD5335, against standard treatments (mirvetuximab soravtansine or chemotherapy) for women with platinum-resistant ovarian cancer. It aims to see if AZD5335 works better based on the level of a protein called FRα on your tumor cells.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05281471RecruitingPhase 3
Tested drug for platinum-resistant ovarian cancer with bevacizumab
This Phase 3 trial tests a treatment made of an investigational gene-based drug plus standard “platinum” chemotherapy and bevacizumab, compared with standard chemotherapy and bevacizumab. It’s for ovarian/fallopian tube/primary peritoneal cancers that have not responded to platinum chemotherapy or came back quickly.
Silver Spring, MarylandAges 18 years+ - NCT07214779RecruitingPhase 3
New drug vs chemo for platinum-resistant ovarian cancer
This study tests a new drug (INCB123667) given as a pill, compared to standard chemotherapy, for people whose ovarian cancer has stopped responding to platinum-based treatments and whose tumor has high levels of a protein called Cyclin E1. The goal is to see if the new drug works better than standard chemo for this specific type of cancer.
Silver Spring, MarylandAges 18 years+ - NCT05579366RecruitingPhase 1/Phase 2
Study drug for advanced ovarian and other solid cancers
This Phase 1/2 trial studies Rinatabart Sesutecan to treat advanced cancers, with special focus on certain ovarian cancer types. It’s meant for people whose cancer has come back or has not responded to prior treatments.
Rockville, MarylandAges 18 years+ - NCT05128825RecruitingPhase 2
Test drug azenosertib for platinum-resistant ovarian cancer
This Phase 2 trial tests azenosertib to treat platinum-resistant high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. It looks for whether the drug can shrink tumors and improve outcomes in people whose cancer has returned after platinum chemotherapy.
Rockville, MarylandAges 18 years+ - NCT06586957RecruitingPhase 1
Study of NKT3964 for advanced solid tumors
This trial is testing an experimental oral drug called NKT3964 for people with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking a protein called CDK2, which some cancers need to grow.
Fairfax, VirginiaAges 18 years+ - NCT06799065RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests ATX-295, a daily pill that blocks a protein called KIF18A, in people with advanced solid tumors, including ovarian cancer. It is for those whose cancer has grown after standard treatments or who cannot have standard therapy.
Fairfax, VirginiaAges 18 years+ - NCT07226427RecruitingPhase 1
Study of MEN2501 for platinum-resistant ovarian cancer
This trial tests a new drug called MEN2501 for people with ovarian cancer that no longer responds to platinum-based chemotherapy. The goal is to see if it is safe and if it can help shrink tumors.
Fairfax, VirginiaAges 18 years+ - NCT07755436RecruitingPhase 1
Study of ARR-002 for advanced ovarian or endometrial cancer
This study tests an experimental drug called ARR-002 in people with advanced or metastatic ovarian, primary peritoneal, or fallopian tube cancer that has stopped responding to standard treatments. The goal is to see if it is safe and whether it shrinks tumors.
Fairfax, VirginiaAges 18 years+ - NCT07278336RecruitingPhase 1
Study of ABBV901 for ovarian cancer
This trial tests a new drug called ABBV901, given alone or with another drug (bevacizumab), for people with a certain type of ovarian cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if it helps control the disease.
Fairfax, VirginiaAges 18 years+ - NCT05867251RecruitingPhase 1/Phase 2
AVZO-021 for advanced breast and ovarian cancers
This early-stage study tests AVZO-021, a new anti-cancer medicine, in people with advanced solid tumors like specific types of breast and ovarian (or related) cancers. It’s meant to find the safest dose and look for signs the medicine can shrink tumors, especially in cancers with certain gene changes.
Fairfax, VirginiaAges 18 years+ - NCT06906341RecruitingPhase 2
Relacorilant combo for gynecologic cancers
This trial tests a drug called relacorilant combined with different treatments for ovarian, fallopian tube, primary peritoneal, or endometrial cancers. It may help patients whose cancer has stopped responding to standard therapies.
Fairfax, VirginiaAges 18 years+ - NCT06824467RecruitingPhase 3
Maintenance Therapy Study for Recurrent Ovarian Cancer
This study tests a new maintenance treatment (sacituzumab tirumotecan) versus standard care for people with ovarian cancer that has come back after responding to platinum-based chemotherapy. The goal is to see if it can keep the cancer from growing longer and improve quality of life.
Fairfax, VirginiaAges 18 years+ - NCT04657068RecruitingPhase 1/Phase 2
Study of ART0380 for advanced solid tumors
This study tests a new drug called ART0380 for people with advanced solid tumors that have not responded to standard treatments. It may be especially helpful for those with certain DNA repair gene changes (like ATM or BRCA). The drug will be given alone or with chemotherapy (gemcitabine or irinotecan) depending on the part of the trial.
Fairfax, VirginiaAges 18 years+ - NCT06690775RecruitingPhase 2
Study of a new drug for platinum-resistant ovarian cancer
This trial tests an investigational drug called TORL-1-23 for people with ovarian cancer that has stopped responding to platinum chemotherapy. It aims to see if the drug can help shrink or control the cancer.
Annapolis, MarylandAges 18 years+ - NCT06617923RecruitingPhase 2
Senaparib and Temozolomide for ARID1A-Mutated Ovarian Cancer
This trial tests a combination of two drugs, senaparib and temozolomide, for women with a specific type of ovarian cancer that has come back or is resistant to platinum-based chemotherapy. It is for patients whose tumor has a change in the ARID1A gene.
Baltimore, MarylandAges 18 years+ - NCT07213804RecruitingPhase 3
Study of sofetabart mipitecan for ovarian cancer
This trial tests a new drug called sofetabart mipitecan for people with ovarian cancer that has come back after treatment. It is for those whose cancer is either resistant to platinum chemo (Part A) or sensitive to it (Parts B and C). The study will see if the drug can help shrink or slow the cancer.
Baltimore, MarylandAges 18 years+
Hear when a new Platinum-resistant Ovarian Cancer trial opens near Washington, D.C., DC
We’ll email you when one opens near Washington, D.C., DC — at most once a week, no account needed, unsubscribe anytime.
Platinum-resistant Ovarian Cancer trials in other cities
Where these studies are running near Washington, D.C.
Institutions with a site for the recruiting platinum-resistant ovarian cancer studies listed above.
- NEXT Oncology · 6 studies
- Virginia Cancer Specialists · 4 studies
- Maryland Oncology Hematology, P.A. · 3 studies
- Greater Baltimore Medical Center · 2 studies
- Holy Cross Hospital · 2 studies
- Inova Schar Cancer Institute · 2 studies
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · 2 studies
- 522
What taking part in a platinum-resistant ovarian cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Common questions
- Are there platinum-resistant ovarian cancer clinical trials near Washington, D.C.?
- Yes. We're currently tracking 18 recruiting platinum-resistant ovarian cancer studies with a site near Washington, D.C., each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a platinum-resistant ovarian cancer study near Washington, D.C.?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Washington, D.C. to take part?
- Not necessarily. These studies have a site near Washington, D.C., but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a platinum-resistant ovarian cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New platinum-resistant ovarian cancer studies open near Washington, D.C. regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.